Cataract Clinical Trial
— STEELEOfficial title:
Clinical Investigation of Rotational Stability of the TECNIS® Toric II Intraocular Lens
Verified date | May 2022 |
Source | Johnson & Johnson Surgical Vision, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a prospective, multicenter, single-arm, open-label clinical study of the commercially available TECNIS Toric II IOL. The study will be conducted in up to 192 subjects needing unilateral or bilateral cataract surgery in up to 8 sites in United States (US). The subjects will be followed for up to 3-months postoperatively.
Status | Completed |
Enrollment | 125 |
Est. completion date | June 1, 2021 |
Est. primary completion date | April 6, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 22 Years and older |
Eligibility | Inclusion Criteria: 1. Minimum 22 years of age; 2. Unilateral or Bilateral cataracts for which cataract extraction and posterior chamber IOL implantation have been planned; 3. Pre-existing corneal astigmatism of one diopter or greater; 4. Predicted residual refractive cylinder based on toric IOL calculator, considering surgically induced astigmatism (SIA) and posterior corneal astigmatism (PCA) must be =0.50 D; 5. Potential for postoperative BCDVA of 20/30 Snellen or better; 6. Clear intraocular media other than cataract in each eye; 7. Availability, willingness and sufficient cognitive awareness to comply with examination procedures and study visits; 8. Signed informed consent form (ICF) and health insurance portability and accountability act (HIPAA) authorization; 9. Ability to understand and respond to a questionnaire in English. Exclusion Criteria: 1. Irregular corneal astigmatism; 2. Any corneal pathology/abnormality other than regular corneal astigmatism or corneal instability due to contact lens wear; 3. Previous corneal or intraocular surgery; 4. Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.); 5. Any pupil abnormalities (non-reactive, fixed, or abnormally shaped pupils); 6. Dilated pupil size of < 6.0 mm; 7. Recurrent severe anterior or posterior segment inflammation or uveitis; 8. Subjects with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration, including pseudoexfoliation, trauma, or posterior capsule defects; 9. Known ocular or systemic disease that, in the opinion of the investigator, may affect visual acuity or require surgical intervention during the course of the study, [macular degeneration, cystoid macular edema, proliferative diabetic retinopathy (severe), uncontrolled glaucoma, irregular corneal astigmatism, choroidal hemorrhage, concomitant severe eye disease, extremely shallow anterior chamber, microphthalmos, non-age related cataract, severe corneal dystrophy, severe optic nerve atrophy, etc.]; 10. Use of systemic or ocular medications (e.g., Flomax) that may affect vision including prior, current, or anticipated use during the course of the study that may, in the opinion of the investigator, confound the outcome or increase the risk to the subject (e.g., poor dilation or a lack of adequate iris structure to perform standard cataract surgery); 11. Patient is pregnant, plans to become pregnant, is lactating or has another condition associated with the fluctuation of hormones that could lead to refractive changes; 12. Concurrent participation or participation within 30 days prior to the preoperative visit in any other clinical study. 13. Planned monovision correction (eye designated for near correction) |
Country | Name | City | State |
---|---|---|---|
United States | Empire Eye and Laser Center, Inc. | Bakersfield | California |
United States | Cincinnati Eye Institute | Cincinnati | Ohio |
United States | JW Eye Associates, P.A. DBA Key-Whitman Eye Center | Dallas | Texas |
United States | Texas Eye & Laser Center, P.A. | Hurst | Texas |
United States | University of California | Los Angeles | California |
United States | Jones Eye Clinic | Sioux City | Iowa |
United States | Vance Thompson Vision, ND | W. Fargo | North Dakota |
Lead Sponsor | Collaborator |
---|---|
Johnson & Johnson Surgical Vision, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Eyes With = 5º Lens Axis Misalignment From the Intended IOL Axis of Orientation at the 1-week Postoperative Visit | Absolute difference between intended IOL axis of orientation (immediately at the end of surgery) and follow-up visit(s) were measured by a photographic based method. | 1 week postoperative |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04685538 -
Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.
|
Phase 3 | |
Recruiting |
NCT06060041 -
IC-8 Apthera IOL New Enrollment Post Approval Study
|
||
Recruiting |
NCT05518539 -
Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
|
||
Recruiting |
NCT05271942 -
Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods
|
N/A | |
Active, not recruiting |
NCT04778501 -
PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia
|
N/A | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT03751033 -
Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings
|
N/A | |
Completed |
NCT02529488 -
Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00
|
N/A | |
Completed |
NCT04539548 -
A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract
|
Phase 3 | |
Completed |
NCT03740659 -
Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery
|
Phase 2 | |
Completed |
NCT03494257 -
Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification
|
N/A | |
Completed |
NCT05119127 -
Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome.
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03713268 -
Intraoperative OCT Guidance of Intraocular Surgery II
|
||
Completed |
NCT03739528 -
Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery
|
Phase 3 | |
Completed |
NCT02888210 -
A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery
|
Phase 3 | |
Completed |
NCT03356847 -
Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery
|
N/A | |
Completed |
NCT04332640 -
Clinical Evaluation of the Next Generation Phaco System
|
N/A | |
Recruiting |
NCT03638726 -
Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification
|
Phase 4 | |
Completed |
NCT03050697 -
Evaluation of the Safety and Performance of the HARMONI® Toric Lens
|
N/A |